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Tuberculosis is the leading infectious cause of death worldwide[1]. One of the three pillars of the 
WHO END-TB strategy is intensified research and innovation, with a focus on the development of 
new interventions to end the global epidemic[2] - shorter, safer, more effective combination 
regimens that result in very high cure rates in programme settings and not just in clinical trials. The 
use of an evidence-based clinical development pathway is essential to ensure that the most effective 
regimens are quickly identified and advanced into phase III definitive evaluation and while dwindling 
resources for TB R&D[3] are not wasted on ineffective regimens. 
What is often described as the traditional clinical development pathway for TB drug and regimen 
development – phase IIA evaluating EBA over 14 days, phase IIB evaluating 2-month culture 
conversion and phase III evaluating relapse – is relatively new. Indeed only the drugs delamanid and 
bedaquiline and the pretomanid-based regimens have strictly followed this pathway (with the phase 
III trials for each still ongoing, clinicaltrials.gov identifiers: NCT01424670, NCT02409290, 
NCT02342886). Historically, the development of regimens for TB did not follow such a formal 
pathway. This development was largely led and funded by public agencies such as the British MRC[4] 
or the US Public Health Service[5] with a focus on trials that invariably included 2-3 years of follow-
up with a primary outcome of relapse. These trials, that would therefore be described today as 
phase III trials, were initiated as soon as there was adequate confidence in the bactericidal and 
sterilizing activities of the individual drugs – the introduction of rifampicin is a case in point[6]. 
Nevertheless, the bacteriological endpoints included in this meta-analysis (Bonnett et al.) continue 
to be the cornerstone of evaluating regimens for progression to phase III and this excellent and 
comprehensive review is timely. While the rank order of regimens is as expected - regimens with 
isoniazid and rifampicin generally perform better than others on all endpoint studied - this is the first 
study to systematically examine the available data in this fashion and therefore provides invaluable 
evidence to support regimen choices and inform future regimen development. However, the 
heterogeneity and variability of the pooled estimates is striking and begs the question: What now is 
the role of these endpoints in regimen development?  
There were no combination regimens with EBA over 2 or 7 days shown to be greater than that of 
isoniazid mono-therapy indicating that these endpoints are not useful for comparing regimens. 
There were fewer regimens evaluated with EBA over 14 days, but the wide confidence intervals 
again show that this endpoint is likely only to detect very large differences between regimens in the 
studies that are typically conducted with 15 patients per arm.  
Considering the endpoint of percentage culture negative at 8 weeks on solid media, there is very 
little difference between the results of any of the regimens containing isoniazid, rifampicin and at 
least one companion drug. Furthermore, the pooled estimate for the standard HRZE regimen is 
around 90% culture negative at 8 weeks leaving very little room for improvement. A trial with even 
80% power to show a difference from 90% to 95% would require 435 patients per arm. The authors 
themselves conclude that current phase IIA and IIB trials are too small to detect modest differences 
between regimens in these studies. It is an open question whether modest differences in these 
phase II endpoints are likely to reflect clinically relevant differences in clinically meaningful 
endpoints but in any case, what are the alternatives? The authors rightly call for more efficient 
adaptive screening trial designs to allow more regimens to be evaluated in phase II trials, and 
sponsors and investigators should also think more broadly about the whole clinical development 
pathway. This review shows the importance of clinically relevant endpoints in TB trials – endpoints 
that measure ‘directly how a patient feels, functions or survives’.[7] A key objective in clinical 
development must be to start studies evaluating relapse as early as is safely possible to select the 
most promising regimens and reduce the risk of large and expensive phase III failures. Approaches to 
meet this objective include the use of larger margins of non-inferiority to facilitate smaller and 
nimbler non-inferiority phase III trials (such as the 12% margin in STAND, NCT02342886), studying a 
regimen in patients with XDR-TB where there is an even greater need for new treatments, and 
studying the intended regimen duration prior to phase III (the STEP Phase IIC design[8]).  
The authors call for more combinations to be studied across a greater range of Phase II endpoints in 
order to provide a more precise evaluation of the role of each endpoint in future meta-analyses. 
While such activities would allow for a better understanding of the role of phase II, this meta-
analysis has highlighted the limitations of these endpoints and there will always be a balance 
between studying more phase II endpoints to fill the data gaps and investing more resources to 
study clinically-relevant endpoints that will be more useful for comparing regimens.  
The authors also highlight the importance of a core outcome set for TB trials and of sharing 
individual patient data from TB trials. These two activities would facilitate further meta-analyses that 
allow for systematising knowledge across trials. There are a relatively small number of groups across 
the world planning and conducting phase II and phase III TB clinical trials and agreement on core 
outcomes should not be an impossible task with support from projects like the COMET initiative[9]. 
Similarly, repositories are now available for TB clinical trial data that investigators and sponsors are 
encouraged to make use of (for example TB-PACTS,  http://c-path.org/programs/tb-pacts/), although 
the resources and expertise required to ensure proper data aggregated and curation and 
appropriate controlled access should not be under-estimated.[10] 
In summary, this well-conducted systematic review provides evidence towards setting tuberculosis 
regimen development on a firm foundation. Further work is needed as more data become available. 
In the interim, clinically relevant endpoints must remain the focus of development of new regimens 
for TB.  
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